Compare HIW & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIW | SUPN |
|---|---|---|
| Founded | 1978 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.0B |
| IPO Year | 1995 | 2010 |
| Metric | HIW | SUPN |
|---|---|---|
| Price | $29.77 | $46.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $27.57 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 1.6M | 586.2K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 8.43% | N/A |
| EPS Growth | ★ 54.26 | N/A |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $806,112,000.00 | $392,755,000.00 |
| Revenue This Year | $6.03 | $22.70 |
| Revenue Next Year | $3.58 | $19.14 |
| P/E Ratio | $100.76 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.45 | $31.16 |
| 52 Week High | $32.76 | $59.68 |
| Indicator | HIW | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 65.43 | 52.65 |
| Support Level | $28.22 | $43.43 |
| Resistance Level | $30.83 | $46.79 |
| Average True Range (ATR) | 0.85 | 1.35 |
| MACD | -0.12 | 0.32 |
| Stochastic Oscillator | 58.79 | 89.83 |
Highwoods Properties Inc is a fully integrated office REIT that owns, develops, acquires, leases, and manages office properties mainly in the best business districts of Atlanta, Charlotte, Dallas, Nashville, Orlando, Raleigh, Richmond, and Tampa. Its principal business is the operation, acquisition, and development of rental office properties, with no material inter-segment transactions. The Company evaluates performance by geographic location, and the operating results by geographic grouping are regularly reviewed by the chief operating decision maker. The core portfolio consists mainly of office properties in its key markets, with the majority of revenue derived from its Raleigh properties.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.